DSM Completes Acquisition of Biomedical Company Kensey Nash

DSM says it has completed the previously announced acquisition of biomedical company Kensey Nash (Exton, PA) for about $360 million, and it is now a an indirect wholly owned subsidiary of DSM. The acquisition was first announced last month and the tender offer to acquire all the outstanding shares of common stock of Kensey Nash concluded on June 18. The acquisition will strengthen and complement DSM’s biomedical business, one of the three emerging business areas of DSM, the company says. Kensey Nash is primarily focused on regenerative medicine utilizing...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers